ICD-10-CM 2027
ICD-10 code for Rising
Rising PSA following treatment for malignant neoplasm of prostate
From the official ICD-10-CM alphabetic index entry “Rising, PSA following treatment for malignant neoplasm of prostate”. Page updated September 29, 2026.
About coding Rising
The ICD-10-CM code for Rising is R97.21 (Rising PSA following treatment for malignant neoplasm of prostate).
Within R97.2 (elevated prostate specific antigen [PSA]), R97.21 is specifically for Rising PSA following treatment for malignant neoplasm of prostate. Related codes cover elevated prostate specific antigen [PSA] (R97.20).
It is not a CC or MCC, so as a secondary diagnosis it doesn't change the MS-DRG severity level.
In MS-DRG v44.0, it is part of the grouping logic for DRG 947 (Signs and Symptoms with MCC, relative weight 1.261) and DRG 948 (Signs and Symptoms without MCC, relative weight 0.7835), in MDC 23 (Factors Influencing Health Status and Other Contacts with Health Services), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.
Common questions about Rising ICD-10 codes
What is the ICD-10 code for Rising?
- R97.21 — Rising PSA following treatment for malignant neoplasm of prostate.
Is R97.21 billable?
- Yes. R97.21 is a billable/specific ICD-10-CM code valid for FY2027 (October 1, 2026 – September 30, 2027).
Can R97.21 be used as a principal diagnosis?
- It can, but When it is the principal diagnosis, Medicare considers it a questionable reason for an inpatient admission, so claims may be reviewed.
Is R97.21 a CC or MCC?
- No. R97.21 is neither a CC nor an MCC under MS-DRG v44.0.